Tucidinostat

DB06334InvestigationalSmall molecule

Investigated for use/treatment in cancer/tumors (unspecified).

Mechanism: Chidamide is an orally bioavailable histone deacetylase (HDAC) inhibitor derived from the benzamide class. Histone deacetylase inhibitors are a class of cancer drugs that induce selective regulation of gene expression in cancer cells. [HUYA Biosciences Press Release]
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Formula / weight: C₂₂H₁₉FN₄O₂ · 390.418 g/mol (avg)
Also known as: Chidamide
Code names: CS-055 · HBI-8000

Resolves to

Compound

UNII87CIC980Y0CAS1616493-44-7ChEMBLCHEMBL3621988ChEBI135918

Clinical / RWD

ATCL01XH06

Structure

InChIKeySZMJVTADHFNAIS-BJMVGYQFSA-NSMILESNC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CN=CC=C2)C=C1

Targets

Q13547HDAC1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

424Drug interactionsStructured to mechanism, not free text

220Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 12 drug categories

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Tucidinostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In